Epigenomics AG (Frankfurt, Prime Standard: ECX), a German listed biotech company focusing on molecular diagnostics, today announced that it has completed an internal review of current operations in the context of its defined business strategy. To maximize its future growth potential and to enforce financial discipline, Epigenomics will focus its product development efforts entirely on later-stage programs in oncology, which are the company’s key value drivers and greatest commercial opportunities. The partnership with Roche Diagnostics will not be affected by this measure. New clinical data from the colorectal and prostate cancer screening programs of this collaboration are expected in December as planned.
